Platycodin D Attenuates Lipopolysaccharide‐Induced Acute Lung Injury by Modulating CD14 ‐Associated Inflammatory Signaling and Macrophage Phenotypic Responses
Year: 2026
Type: article
Abstract: Acute lung injury (ALI) is characterized by excessive pulmonary inflammation and lacks effective targeted pharmacotherapies. This study investigated the protective effects of Platycodin D (PLD) in lipopolysaccharide (LPS)-induced ALI and explored the involvement of CD14-associated inflammatory signaling and macrophage phenotypic regulation. Male C57BL/6 mice were challenged with intratracheal LPS and subsequently treated with PLD by inhalation (5 and 10 mg/kg) or intravenous injection (1 and 2 mg/kg), with dexamethasone (5 mg/kg, i.p.) as the positive control. PLD alleviated histopathological lung injury, reduced the lung index, pulmonary MPO levels, neutrophil infiltration, and pro-inflammatory cytokines, and modulated macrophage-associated inflammatory phenotypes. RNA-seq analysis identified prominent regulation of NF-κB and NOD-like receptor signaling. Molecular docking, cellular co-localization, CETSA, and DARTS analysis provided complementary evidence consistent with a possible interaction involving CD14. PLD suppressed TLR4/MyD88/NF-κB signaling and downstream NLRP3 inflammasome-associated responses in both lung tissue and macrophage models. In macrophages, PLD reduced M1-associated markers and increased M2-associated markers. CD14 knockdown altered these inflammatory and polarization responses, supporting a functional contribution of CD14, although PLD retained regulatory effects on several downstream markers after CD14 silencing. Collectively, these findings indicate that PLD attenuates LPS-induced ALI through modulation of CD14-associated inflammatory signaling and macrophage phenotypic regulation. The efficacy observed following both nebulized and intravenous administration provides a basis for further pharmacokinetic and translational evaluation of PLD.
Source: Phytotherapy Research
DOI: 10.1002/ptr.70523
Institution: Guangxi University of Chinese Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,880
OpenAlex ID: W7233951929
